A 60-year-old woman suffering from severe chronic post-herpetic neuralgia (PHN) was treated with simple autologous fat grafting to the affected area of skin. Post-operatively, she reported a great improvement in her symptoms. The effect was stable throughout the 3-month follow-up period. This case report presents a first-in-the-world case of using fat grafting to treat chronic post-herpetic neuralgia and discusses the future potential of this as a primary treatment of this syndrome. This report presents partial data of a pilot study registered at clinicaltrials.org (ClinicalTrials.gov Identifier: NCT03584061).
Introduction
Post-herpetic neuralgia (PHN) is a neuropathic pain syndrome occurring after an outbreak herpes zoster (HZ) or 'shingles'. It is caused by a reactivation of varicella zoster virus (VZV). 1, 2 The risk of developing PHN after HZ is reported being between 5% and 30%, and the pain can last up to 10 years. 3 Clinically, the disease is characterised by a painful, unilateral vesicular eruption, which usually occurs with limited dermatomal distribution. 1 Pain is the predominant symptom in all phases of the disease and is reported in up to 90% of patients. 4 Most patients with PHN describe three types of pain: a constant deep, aching or burning pain; a paroxysmal, lancinating pain; and allodynia. 5 Treatment of PHN is complex, and the neuropathic pain is exceptionally drug-resistant. 5 Several broad recommendations on treatment of the neuropathic pain have been published. [6] [7] [8] There is, however, currently no internationally accepted guideline of treating PHN. 1 Treatment consists of topically and systemically administered medication. The present standard of care in not very effective, and new treatments are needed. One such approach is autologous fat grafting. Fat tissue is abundant in most individuals, and fat grafting is a safe and simple procedure. Fat grafting has shown potential in treating several painful conditions, such as post-mastectomy pain and scar-related pain, but it has not previously been used to treat PHN. [9] [10] [11] 
Case report
The patient was a 60-year-old woman with pain in the areas of the previous shingles-rash. The reactivation of VZV had occurred 3 years previously. The area of outbreak measured 30 cm × 10 cm and stretched from the right side of the abdomen backwards towards the columna. The patient described the pain in the affected areas as a constant burning, throbbing pain. She had previously tried several pain medications for her condition without any effect. The medications tried were paracetamol, ibuprofen, tramadol and gabapentin. As she felt they had no effect, she had stopped taking them prior to beginning our treatment. The affected area was marked pre-operatively by the surgeon and the patient. The marked area can be seen in Photo 1. The patient was thoroughly informed of the potential risks of the procedure and signed a written consent form prior to surgery.
Treatment
The procedure was performed under general anaesthesia. Liposuction (body-jet; Human med AG, Schwerin, Germany, http://www.humanmed.com) was performed by harvesting fat from the abdomen. Prior to harvesting, the area was prepared by installing ringer-adrenalin solution. In total, 300 cc of fat was harvested. The fat was then decanted. After 15 minutes, 120 cc of fat was injected sub-dermally in the marked area of pain using 10-mL cannulas.
The patient was then fitted with a compression belt for the area of liposuction. The patient was discharged the same afternoon.
Investigations
Outcomes measured were degree and quality of neuropathic pain and quality of life. Neuropathic pain was measured using the questionnaire: Neuropathic Pain Symptom Inventory Scale (NPSI). 12 Quality of life was measured using the Short Form 36 (SF-36) questionnaire. [13] [14] [15] All questionnaires have validated translations into Danish. 12, 15 The questionnaire was filled by the patient pre-operatively and 3 months postoperatively.
Effect of treatment
A few days after the surgery, the patient reported improvement of her symptoms. This continued throughout the follow-up period. The patient experienced improvement in all measured parameters. Quality of life was measured using the SF-36 questionnaire. The patient reported improvement in all qualityof-life parameters (Figure 1) . The degree and quality of pain were measured using the NPSI. The patient reported improvement in all types of recorded pain ( Figure 2 ). The patient did not report any disturbances in the sensation of the skin. There was no cosmetic effect of the treatment and no severe side effects were observed.
Discussion

Relevance of treatment
One in four people will suffer from HZ in their lifetime, and the risk is markedly increased after the age of 50 years, with an incidence of almost 50% in elderly individuals. The prevalence of PHN will likely increase in the future as the population ages. The resolve of the disease is slow, and the disease has been shown to have a negative impact on quality of life. [16] [17] [18] Today's treatment regimen of medications has potentially serious side effects and the risk of addiction. It is, therefore, important that we find an effective way of treating these patients. Photo 1. The area of pain marked pre-operatively. The area marked with cross-markings was the area with the most predominant pain. This was the area where fat-injection was performed.
Pathophysiology
The pathophysiology behind HZ and PHN is neural damage to both the peripheral and central nervous system. HZ also induces neuroinflammation, a process that normally promotes regeneration and healing. If the resolution of neuroinflammation is disturbed, the result may be chronic pain. 19, 20 The direct damage and continued inflammation lower the threshold for action potentials, causing the nerves to fire painful signals, even by non-painful stimuli. 21 Skin biopsies of people affected by HZ and PHN have shown a lowered number of free epidermal nerve endings, with an even lower number in people with PHN compared to HZ alone. 22 The aim of treatment should, therefore, be to modulate the signalling by the nerve endings by resolving the neuroinflammation and by repairing the damage and possibly help increase the number of free epidermal nerve ending.
Fat grafting, safety and possible effect
Fat grafting has been used for many years and has proven to be a simple and safe procedure. The most common side effects such as numbness, bruising, pain, swelling, infection and changes in skin sensation are usually mild and easily treated. Fat grafting has shown potential in treating painful conditions such as post-mastectomy pain syndrome, painful neuromas and painful scars [9] [10] [11] 23 The exact mechanism of fat grafting on painful conditions is not known, and there are several theories being debated. First, fat grafting has a potential anti-inflammatory effect. In mouse model studies, fat grafting to the sub-dermal tissues has shown an anti-inflammatory effect, both in the skin and in the spinal cord. The level of neuropathic pain was also reduced. 24 The stem cells within the fatty tissue could also play a role in the pain-relieving effect. Adipose-derived stem cells (ADSC) have shown the ability to secrete several different growth factors in vitro, possibly inducing repair of damaged nerves. 25 The use of ADSC alone has also proven to have a pain-relieving effect in people affected by neuropathic trigeminal pain. 26 The third possible effect could be the injected fats ability to act as a filler that cushions and improves chronic pain. In our study, this is unlikely as the amount of injected fat was very small. Fat grafting is also a relatively inexpensive treatment. When the liposuction equipment has been acquired, the cost of each individual treatment is low. Although no costbenefit analysis has been performed, we would argue that a single treatment of fat grafting is preferable compared to a lifetime of medications.
We believe that the method presented could be a potential treatment for patients affected by PHN. Future studies are needed to investigate the effect.
This case study is a part of a pilot study currently undergoing at our department. Based on the promising preclinical and clinical results, we are planning a phase II study in our department to further test the feasibility and safety of this procedure (ClinicalTrials.gov Identifier: NCT03584061)
